CA
NZ
UK
AU
IND
US
Apyx Medical occupies a distinctive position in the medical technology landscape as the developer of Renuvion, a helium plasma-based energy delivery platform cleared by the FDA for use in multiple aesthetic and surgical body contouring applications. Unlike the clinical-stage companies in this sector, Apyx …
Insulet Corporation (Nasdaq:PODD) beat Q1 2026Earningsexpectations with 34%Revenuegrowth and a 40% EPS surge, yet shares fell nearly 10%. Here is what the numbers reveal.Key HighlightsQ1 2026 revenue rose 34% year-over-year to USD 761.7 million, exceeding the analyst consensus of USD 728.36 million.Adjusted EPS of …
A Preclinical Result That Commands Attention
Revenue Growth Intact, Profitability Under Strain
On the surface, the most newsworthy item surrounding Edgewise Therapeutics on Tuesday was a significant insider sale. Chief Medical Officer Joanne M. Donovan disclosed the sale of 55,230 shares across two transactions — 5,230 shares at $31.29 on May 4 and a much larger …
To appreciate why Fate Therapeutics shares surged 31% to $2.36 on Tuesday, it is necessary to understand what the FDA's CMC Development and Readiness Pilot Program actually represents — and why selection is a far more meaningful event than its understated name suggests.
Biodesix delivered a first-quarter 2026 earnings report that, by any measure, represents a genuine commercial inflection for the lung diagnostics company. Revenue of $25.6 million grew 42% year over year — a growth rate that is exceptional for a commercial-stage diagnostics business and reflects …
To understand why the EMANATE miss matters — and why it doesn't necessarily spell the end of the road — you need to understand what Setmelanotide is and what Rhythm has been trying to build with it.
Small and micro-cap biotechnology enters May 2026 in a state of historic bifurcation. Large-cap pharmaceutical companies AbbVie facing the Humira cliff, Bristol-Myers Squibb managing Revlimid and Eliquis losses, Pfizer navigating post-COVID revenue normalisation are sitting on record cash balances and facing imminent patent cliffs …
Revenue Growth Driven by IMCIVREE Commercial Expansion
Please wait processing your request...